Cargando…

SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination

(1) Background: SARS-CoV-2 T cell immunity is rapidly activated following SARS-CoV-2 infection and vaccination and is crucial for controlling infection progression and severity. The aim of the present study was to compare the levels of T cell responses to SARS-CoV-2 between cohorts of subjects with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitiriga, Vassiliki C., Papamentzelopoulou, Myrto, Konstantinakou, Kanella E., Theodoridou, Kalliopi, Vasileiou, Irene V., Tsakris, Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384199/
https://www.ncbi.nlm.nih.gov/pubmed/37515000
http://dx.doi.org/10.3390/vaccines11071186
_version_ 1785081099154620416
author Pitiriga, Vassiliki C.
Papamentzelopoulou, Myrto
Konstantinakou, Kanella E.
Theodoridou, Kalliopi
Vasileiou, Irene V.
Tsakris, Athanasios
author_facet Pitiriga, Vassiliki C.
Papamentzelopoulou, Myrto
Konstantinakou, Kanella E.
Theodoridou, Kalliopi
Vasileiou, Irene V.
Tsakris, Athanasios
author_sort Pitiriga, Vassiliki C.
collection PubMed
description (1) Background: SARS-CoV-2 T cell immunity is rapidly activated following SARS-CoV-2 infection and vaccination and is crucial for controlling infection progression and severity. The aim of the present study was to compare the levels of T cell responses to SARS-CoV-2 between cohorts of subjects with hybrid immunity (convalescent and vaccinated), vaccinated naïve (non-exposed) and convalescent unvaccinated subjects. (2) Methods: We performed a retrospective descriptive analysis of data collected from the medical records of adult individuals who were consecutively examined at a large, private Medical Center of Attica from September 2021 to September 2022 in order to be examined on their own initiative for SARS-CoV-2 T cell immunity response. They were divided into three groups: Group A: SARS-CoV-2 convalescent and vaccinated subjects; Group B: SARS-CoV-2 naïve vaccinated subjects; Group C: SARS-CoV-2 convalescent unvaccinated subjects. The SARS-CoV-2 T cell response was estimated against spike (S) and nucleocapsid (N) structural proteins by performing the methodology T-SPOT.COVID test. (3) Results: A total of 530 subjects were retrospectively included in the study, 252 females (47.5%) and 278 (52.5%) males ranging from 13 to 92 years old (mean 55.68 ± 17.0 years). Among them, 66 (12.5%) were included in Group A, 284 (53.6%) in Group B and 180 (34.0%) in Group C. Among the three groups, a reaction against S antigen was reported in 58/66 (87.8%) of Group A, 175/284 (61.6%) of Group B and 146/180 (81.1%) of Group C (chi-square, p < 0.001). Reaction against N antigen was present in 49/66 (74.2%) of Group A and in 140/180 (77.7%) of Group C (chi-square, p = 0.841). The median SFC count for S antigen was 24 (range from 0–218) in Group A, 12 (range from 0–275) in Group B and 18 (range from 0–160) in Group C (Kruskal–Wallis test, p < 0.001; pairwise comparisons: groups A–B, p < 0.001; groups A–C, p = 0.147; groups B–C, p < 0.001). The median SFCs count for N antigen was 13 (range 0–82) for Group A and 18 (range 0–168) for Group C (Kruskal–Wallis test, p = 0.27 for A–C groups). (4) Conclusions: Our findings suggest that natural cellular immunity, either alone or combined with vaccination, confers stronger and more durable protection compared to vaccine-induced cellular immunity.
format Online
Article
Text
id pubmed-10384199
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103841992023-07-30 SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination Pitiriga, Vassiliki C. Papamentzelopoulou, Myrto Konstantinakou, Kanella E. Theodoridou, Kalliopi Vasileiou, Irene V. Tsakris, Athanasios Vaccines (Basel) Article (1) Background: SARS-CoV-2 T cell immunity is rapidly activated following SARS-CoV-2 infection and vaccination and is crucial for controlling infection progression and severity. The aim of the present study was to compare the levels of T cell responses to SARS-CoV-2 between cohorts of subjects with hybrid immunity (convalescent and vaccinated), vaccinated naïve (non-exposed) and convalescent unvaccinated subjects. (2) Methods: We performed a retrospective descriptive analysis of data collected from the medical records of adult individuals who were consecutively examined at a large, private Medical Center of Attica from September 2021 to September 2022 in order to be examined on their own initiative for SARS-CoV-2 T cell immunity response. They were divided into three groups: Group A: SARS-CoV-2 convalescent and vaccinated subjects; Group B: SARS-CoV-2 naïve vaccinated subjects; Group C: SARS-CoV-2 convalescent unvaccinated subjects. The SARS-CoV-2 T cell response was estimated against spike (S) and nucleocapsid (N) structural proteins by performing the methodology T-SPOT.COVID test. (3) Results: A total of 530 subjects were retrospectively included in the study, 252 females (47.5%) and 278 (52.5%) males ranging from 13 to 92 years old (mean 55.68 ± 17.0 years). Among them, 66 (12.5%) were included in Group A, 284 (53.6%) in Group B and 180 (34.0%) in Group C. Among the three groups, a reaction against S antigen was reported in 58/66 (87.8%) of Group A, 175/284 (61.6%) of Group B and 146/180 (81.1%) of Group C (chi-square, p < 0.001). Reaction against N antigen was present in 49/66 (74.2%) of Group A and in 140/180 (77.7%) of Group C (chi-square, p = 0.841). The median SFC count for S antigen was 24 (range from 0–218) in Group A, 12 (range from 0–275) in Group B and 18 (range from 0–160) in Group C (Kruskal–Wallis test, p < 0.001; pairwise comparisons: groups A–B, p < 0.001; groups A–C, p = 0.147; groups B–C, p < 0.001). The median SFCs count for N antigen was 13 (range 0–82) for Group A and 18 (range 0–168) for Group C (Kruskal–Wallis test, p = 0.27 for A–C groups). (4) Conclusions: Our findings suggest that natural cellular immunity, either alone or combined with vaccination, confers stronger and more durable protection compared to vaccine-induced cellular immunity. MDPI 2023-06-30 /pmc/articles/PMC10384199/ /pubmed/37515000 http://dx.doi.org/10.3390/vaccines11071186 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pitiriga, Vassiliki C.
Papamentzelopoulou, Myrto
Konstantinakou, Kanella E.
Theodoridou, Kalliopi
Vasileiou, Irene V.
Tsakris, Athanasios
SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination
title SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination
title_full SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination
title_fullStr SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination
title_full_unstemmed SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination
title_short SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination
title_sort sars-cov-2 t cell immunity responses following natural infection and vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384199/
https://www.ncbi.nlm.nih.gov/pubmed/37515000
http://dx.doi.org/10.3390/vaccines11071186
work_keys_str_mv AT pitirigavassilikic sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination
AT papamentzelopouloumyrto sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination
AT konstantinakoukanellae sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination
AT theodoridoukalliopi sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination
AT vasileiouirenev sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination
AT tsakrisathanasios sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination